Inhibitory Effect Of Calcitonin Research Articles

Effect of Calcium-Regulating Hormones and Calcium Channel Modulators on Glucose Consumption by Muscle and Adipose Tissues In Vivo and In Vitro

We studied the effects of calcitonin, parathyrin, and Ca(2+) channel antagonist isoptin and agonist Bay-K-8644 on glucose consumption by muscle (diaphragm) and adipose (epididymal) tissues and insulin-stimulated glucose consumption in vivo and in vitro. Calcitonin and parathyrin did not alter glucose consumption; parathyrin did not affect, while calcitonin completely abolished the stimulating effect of insulin in vivo and in vitro. Isoptin significantly increased glucose consumption in vivo and in vitro, while Bay-K-8644 in vitro had no effect glucose consumption. Isoptin did not affect, while Bay-K-8644 significantly reduced the stimulating effect of insulin on glucose consumption by the muscle and adipose tissues. Isoptin did not affect the stimulating effect of insulin against the background of parathyrin administration and completely blocked the inhibitory effect of calcitonin on insulin-stimulated glucose consumption by the muscle and adipose tissues in vivo and in vitro, while Bay-K-8644 potentiated this effect of calcitonin in vitro.

Effects of calcitonin on osteoclast

Osteoclasts are the only cells that destroy and resorb bone. Calcitonin, a calcium regulatory hormone, strongly inhibits bone-resorbing activity of osteoclasts. The calcitonin-induced inhibition of osteoclast function is believed to be due to disruption of cytoskeletal organization (distraction of actin rings) and disappearance of the cellular polarity of osteoclasts. Calcitonin receptors are coupled to both cAMP-PKA- and Ca(2+)-PKC (protein kinase C)-mediated signaling pathways. Using mouse osteoclasts formed in vitro, it is shown that inhibitory effects of calcitonin on bone resorption is mainly mediated by the cAMP-PKA signal. This article describes the mechanism of calcitonin action in the suppression of osteoclast function.

Novel calcitonin-(8–32)-sensitive adrenomedullin receptors derived from co-expression of calcitonin receptor with receptor activity-modifying proteins

We tested whether heterodimers comprised of calcitonin (CT) receptor lacking the 16-amino acid insert in intracellular domain 1 (CTR I1−) and receptor activity-modifying protein (RAMP) can function not only as calcitonin gene-related peptide (CGRP) receptors but also as adrenomedullin (AM) receptors. Whether transfected alone or together with RAMP, human (h)CTR I1− appeared mainly at the surface of HEK-293 cells. Expression of CTR I1− alone led to significant increases in cAMP in response to hCGRP or hAM, though both peptides remained about 100-fold less potent than hCT. However, the apparent potency of AM, like that of CGRP, approached that of CT when CTR I1− was co-expressed with RAMP. CGRP- or AM-evoked cAMP production was strongly inhibited by salmon CT-(8–32), a selective amylin receptor antagonist, but not by hCGRP-(8–37) or hAM-(22–52), antagonists of CGRP and AM receptors, respectively. Moreover, the inhibitory effects of CT-(8–32) were much stronger in cells co-expressing CTR I1− and RAMP than in cells expressing CTR I1− alone. Co-expression of CTR I1− with RAMP thus appears to produce functional CT-(8–32)-sensitive AM receptors.

Calcitonin decreases the adherence and survival of HEK-293 cells by a caspase-independent mechanism.

We recently reported that calcitonin (CT) can profoundly inhibit the growth of HEK-293 cells transfected with the human calcitonin receptor (hCTR). We also obtained preliminary evidence that suggested a role for CT in cell survival, and in the present study we have investigated the pro-apoptotic action of CT, which we observe in conditions of low serum concentration. Under these conditions, we have found that CT treatment of HEK-293 cells stably transfected with the insert-negative form of the human CTR (HR12 cells) caused a time-dependent decrease in cell number associated with loss of cellular attachment. Loss of cellular adherence in CT-treated cultures caused programmed cell death, as shown by Annexin V staining of cells, failure of cells to exclude Trypan Blue dye, condensation and cleavage of nuclear DNA, and appearance of hypodiploid cells in fluorescence-activated cell sorting (FACS) analysis. The accumulation of non-adherent cells and cell death was concomitant with increased intracellular activity of caspase-3. However, inhibition of caspase activation in HR12 cells did not prevent CT-mediated loss of attachment and did not maintain the viability of non-adherent cells, indicating that caspase activation accompanied, but was probably not the cause of, the loss of cell viability. Neither the effects of CT on cell survival nor the activation of caspase-3 were observed in serum-replete conditions, suggesting that serum-derived factors provide protection of cells from CT-induced apoptosis. The inhibitory effects of CT on cell growth were found previously to be related to activation of Erk1/2 MAP kinase. In the present experiments, it was found that the Erk1/2 inhibitor, PD 98059, inhibited the CT-induced loss of cellular adherence and the consequent reduction in cell numbers. These results demonstrate that CT can negatively affect cell survival and they identify roles for cell adherence and MAP kinase activation in this process.

Calcitonin receptor regulation and responsiveness to calcitonin in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor-kappaB ligand and macrophage colony-stimulating factor.

Using mouse osteoclast-like cells (OCs), we have shown that short exposure to calcitonin (CT) resulted in prolonged reduction of CT binding by inhibiting de novo CT receptor (CTR) synthesis. Additionally, CT-treated OCs demonstrated resistance to CT rechallenge on the inhibitory effect of CT in osteoclastic bone resorption. There is, however, scant information on CT effects on human osteoclasts. In this study, we examined the features of CTR down-regulation and its recovery after short exposure to CT of human OCs. OCs were prepared by treatment of peripheral blood mononuclear cells in vitro with osteoclast differentiation factor and macrophage colony-stimulating factor. Treatment of OCs with salmon CT (sCT) and human CT (hCT) resulted in a dose-dependent reduction in [125I]sCT binding capacity. Continued receptor occupancy by ligand was excluded by using a glycine-acid washing procedure. Treatment with sCT reduced CTR messenger RNA expression, suggesting that CTR down-regulation is, at least partly, attributable to an inhibition of de novo CTR synthesis. To investigate the intracellular signal transduction pathways that mediate these effects, we examined the effects of activation of the protein kinase (PK)A, PKC, and Ca2+-calmodulin-dependent kinases. Treatment with PKC activators mimicked CT, whereas neither activation of PKA nor elevation of intracellular Ca2+ did so. We further investigated the intracellular signaling pathways responsible for the inhibitory effects of CT on bone resorption, which showed that treatment with PKC activators reproduced the effects of CT. These data suggest that the PKC pathway plays an important role in homologous CTR down-regulation, as well as inhibition of bone-resorbing activity by CT, in human OCs. Short exposure of OCs to CT (10(-9) M, 1 h) reduced [125I]sCT-specific binding for a prolonged period, as we have shown previously in mouse OCs. The reduced specific binding, CTR messenger RNA levels, and CT-sensitive adenylate cyclase responsiveness returned to the control levels by 96 h after removal of CT. These results strongly support the notion that escape from CT inhibition of osteoclastic bone resorption in humans is attributable to the development of resistance by OCs to CT. This study also showed that even short exposure to CT induced prolonged desensitization to CT rechallenge, although the OCs eventually regained responsiveness to sCT rechallenge.

23( S )25( R )-1,25-Dihydroxyvitamin D 3 -lactone, a naturally occurring metabolite of 1,25-dihydroxyvitamin D 3 , inhibits osteoclast-like cell formation in human bone marrow cultures

We have used a human bone marrow culture system that forms multinucleated cells (MNCs), 50% of which express the osteoclast phenotype, to examine the 23(S)25(R)-1,25-dihydroxyvitamin D3-26,23-lactone (1,25-D3-lactone) on osteoclast-like cell formation. The 1,25-D3-lactone is a vitamin D3 metabolite that has recently been detected in human serum under physiological conditions at concentrations of approximately 131 pg/ml (3 × 10−10 M) and can inhibit bone resorption induced by 1,25-dihydroxyvitamin D3 (1,25-D3) in vivo and in vitro. We examined the effects of the 1,25-D3-lactone on the formation of MNC that cross-reacted with 23C6 monoclonal antibody (23C6-positive MNC), which preferentially binds to osteoclasts. All metabolites of 1,25-D3 except the 1,25-D3-lactone increased both total and 23C6-positive MNC formation in a dose-dependent manner. In contrast, the 1,25-D3-lactone inhibited both total and 23C6-positive MNC formation, whether the cultures were treated with 1,25-D3, parathyroid hormone, or interleukin-1β, all potent stimulators of MNC formation. This inhibitory action of 1,25-D3-lactone on MNC formation was very similar to the inhibitory effects of calcitonin. These data suggest that (1) 1,25-D3-lactone is a potent natural inhibitor of formation of cells with the osteoclast phenotype at physiological concentrations and (2) the inhibition of these cells by 1,25-D3-lactone may not result solely from its competitive binding to the 1,25-D3 receptor.

Fetal calcium homeostasis

The mammalian fetus is maintained hypercalcaemic relative to its mother primarily by the action of a placental calcium pump located in the basal plasma membrane of the trophoblast. It is suggested that the activity of this pump is stimulated by a mid-molecular fragment of parathyroid hormone-related protein [PTHrP(38-94NH2)], produced in the placenta (and also in the parathyroid glands of fetal lambs and calves) as a result of post translational processing. In the sheep, calcitriol is an important determinant of fetal calcium homeostasis and it, too, stimulates the transport of calcium across the placenta. Fetal bone resorption is under the control of calcitriol, parathyroid hormone (PTH) and PTHrP. This resorption is modulated by the inhibitory effect of calcitonin. PTHrP also plays an important role in the regulation of endochondral ossification and chondrocyte maturation.

Expression of the calcitonin receptor in bone marrow cell cultures and in bone: a specific marker of the differentiated osteoclast that is regulated by calcitonin.

We studied the temporal sequence of osteoclast (OC) differentiation from precursor cells in murine marrow cultures. Two markers of the OC phenotype, calcitonin (CT) receptor (CTR) and tartrate resistant acid phosphatase (TRAP), were assessed. Marrow cells from C57BL/6 mice were cultured for 3, 5, 7, and 9 days with or without 1,25-(OH)2vitamin D3 (10(-8) M). In controls only small numbers of osteoclastic multinucleated cells 9MNCs) formed per well (< 15 per well). In contrast, 1,25-(OH)2D3 strongly stimulated MNC formation (> 80 per well on day 7). Messenger RNA (mRNA) for TRAP was detectable by reverse transcription-polymerase chain reaction amplification in both control and 1,25-(OH)2D3 treated groups at all times. However, TRAP mRNA was detectable in MNCs by the less sensitive in situ hybridization only on days 5, 7, and 9 and only in 1,25-(OH)2D3 treated cells. In control cultures, CTR mRNA was present on day 3 only in nonadherent cells and was not present in adherent cells (where MNCs formed) at any time point. In 1,25-(OH)2D3 treated cultures CTR mRNA was detectable in nonadherent cells on day 3 and in adherent cells on day 5 and thereafter. Peak levels of CTR mRNA were seen in adherent cells on day 7 (15-fold more than day 5 and 4-fold more than day 9). CT (10(-7) M) treatment of 7 day cultures, which had been stimulated to express the osteoclastic phenotype, caused a marked decrease in CTR mRNA expression at 24 h. There was no effect of CT treatment on CTR mRNA expression at 3 h or on TRAP mRNA expression at 3 or 24 h. In neonatal mouse calvaria cultures, CTR mRNA expression was constitutively present and was markedly decreased by 48 h of CT treatment. Similarly, bone resorption in these cultures was inhibited at 24 h by CT treatment, but at 48 and 72 h there was escape from the inhibitory effects of CT on resorption. In the marrow cultures, MNCs were greater than 98% positive for [125I]-salmon calcitonin (sCT) binding and this binding was completely competed away by excess cold sCT (10(-7) M). All primary isolated osteoclasts from 1- to 3-day-old mouse long bones exhibited [125I]-sCT binding and TRAP activity and were strongly positive for CTR and TRAP mRNA by in situ hybridization. Both MNCs that formed in bone marrow cultures and isolated primary osteoclasts formed resorption pits on bone slices.(ABSTRACT TRUNCATED AT 400 WORDS)

Novel cell-surface Ag expressed on rat osteoclasts regulating the function of the calcitonin receptor.

Osteoclasts are known to be hematopoietic in origin. However, the detailed mechanisms of their differentiation and activation are not known. Cell-surface molecules preferentially expressed on cells of the osteoclast lineage may play some important roles in these processes. We prepared a mAb that recognizes a unique cell-surface membrane protein specifically expressed on rat osteoclasts. Expression of this Ag, designated as Kat1 Ag, was markedly stimulated by a factor secreted by the osteoblastic cell line ROS 17/2.8. Binding studies of 125I-labeled calcitonin (CT) showed that the Ag was not the CT receptor (CTR). However, interestingly, studies of the biologic activity of this mAb that recognizes Kat1-antigen (mAb Kat1) revealed possible regulatory functions of this Ag in osteoclasts. Firstly, mAb Kat1 significantly elevated the binding affinity of the CTR expressed on osteoclast-like cells without altering the number of receptors. Secondly, CT-sensitivity of the osteoclast progenitor cells in the system of osteoclast differentiation showed marked augmentation on treatment of these cells with this mAb. Even a very low concentration of CT (0.1 ng/ml) significantly inhibited osteoclast differentiation in the presence of mAb Kat1, whereas a higher concentration of CT (10 ng/ml) was required to inhibit their differentiation in the absence of this mAb. Thirdly, mAb Kat1 inhibited dentin-resorbing activity of osteoclast-like cells. Furthermore, the inhibitory effects of CT on osteoclast-mediated dentin resorption was augmented by the presence of this mAb. These observations strongly suggest that Kat1-antigen is a unique cell-surface protein regulating the affinity of the CTR expressed on osteoclasts and also the bone-resorbing function of these cells.

Hormonal regulation of pp60c-src expression during osteoclast formation in vitro.

Recent studies have shown that the protooncogene c-src is required for normal osteoclastic bone resorption. In this study we examined the expression and regulation of pp60c-src in murine bone marrow cultures in which bone-resorbing multinucleated osteoclasts form over 6 days of culture. We found that both pp60c-src protein expression and pp60c-src tyrosine kinase activity correlated closely with the numbers of active osteoclasts in the cultures. PTH increased the numbers of osteoclasts, pp60c-src tyrosine kinase activity, and src protein, whereas calcitonin decreased the numbers of osteoclasts, src protein, and tyrosine kinase activity. However, when calcitonin was incubated for short periods (< 2 h) with the active osteoclasts present after 6 days of culture, there was a decrease in pp60c-src tyrosine kinase activity and the phosphorylation state, but not in total pp60c-src protein. These data suggest that pp60c-src is expressed in cultures of osteoclasts in parallel with the number of active bone-resorbing osteoclasts. They indicate that pp60c-src activity in osteoclast cultures depends on the activity and numbers of osteoclasts and is hormone regulated. As calcitonin receptors are detectable only in osteoclasts in these cultures, the inhibitory effects of calcitonin suggest that the critical site for pp60c-src expression in these cultures is in osteoclasts.

Regucalcin modulates hormonal effect on (Ca(2+)-Mg2+)-ATPase activity in rat liver plasma membranes.

The interaction of various hormones and regucalcin on (Ca(2+)-Mg2+)-ATPase activity in rat liver plasma membranes was investigated. The presence of epinephrine (10(-6)-10(-4) M), phenylephrine (10(-6)-10(-4) M), and insulin (10(-8)-10(-7) M) in the reaction mixture produced a significant increase in (Ca(2+)-Mg7+)-ATPase activity, while the enzyme activity was decreased significantly by calcitonin (3 x 10(-8)-3 x 10(-6) M). These hormonal effects, except for calcitonin, were clearly inhibited by the presence of vanadate (10(-4) M) which can inhibit the Ca(2+)-dependent phosphorylation of enzyme. Meanwhile, regucalcin (0.25 and 0.50 microM), isolated from rat liver cytosol, elevated significantly (Ca(2+)-Mg2+)-ATPase activity in the plasma membranes, although this elevation was not inhibited by vanadate (10(-4) M). The epinephrine (10(-5) M) or phenylephrine (10(-4) M)-induced increase in (Ca(2+)-Mg2+)-ATPase activity was disappeared in the presence of regucalcin; in this case the effect of regucalcin was also weakened. However, the inhibitory effect of calcitonin (3 x 10(-6) M) was not weakened by the presence of regucalcin (0.5 microM). Moreover, GTP (10(-5) and 10(-4) M)-induced increase in (Ca(2+)-Mg2+)-ATPase activity was not seen in the presence of regucalcin (0.25 microM). The present finding suggests that the activating mechanism of regucalcin on (Ca(2+)-Mg2+)-ATPase is not involved on GTP-binding protein which modulates the receptor-mediated hormonal effect in rat liver plasma membranes.

Differential effects of the 3',5'-cyclic adenosine monophosphate and protein kinase C pathways on the response of isolated rat osteoclasts to calcitonin

Calcitonin (CT) activates both the cAMP and the protein kinase C (PKC) pathways in the kidney cell line LLC-PK1. Although CT also activates cAMP in osteoclasts, its effects on PKC in this cell type are unknown. In order to determine whether the response of osteoclasts to CT also involves the PKC pathway, the effects of activators and inhibitors of PKC on bone resorption and cell surface area were analyzed in isolated rat osteoclasts. As expected, CT inhibited in a dose-dependent manner bone resorption by rat osteoclasts cultured for 24 h on devitalized bovine bone slices and this effect could be mimicked by cAMP. The inhibitory effect of CT could however also be mimicked by phorbol-12,13-dibutyrate (PDBu) and blocked by the PKC inhibitor sphingosine, as well as by the less specific inhibitors H7 and H8, none of which had detectable effects in the absence of CT. No changes in the number of attached osteoclasts were observed under any of these conditions. These results indicate that CT activates PKC in osteoclasts and that this activation, like the activation of cAMP-dependent protein kinase, leads to an inhibition of bone resorption. Quantitative time-lapse videomicroscopy showed that the CT-induced retraction of osteoclasts also involved activation of the PKC pathway and could therefore be induced by phorbol esters. In contrast, (Bu)2 cAMP (1-200 microM) failed to induce rapid cell retraction. It is concluded that, in osteoclasts, CT receptors are coupled to both the cAMP-dependent protein kinase and the PKC pathways. Although these two second messengers can have additive inhibitory effects on bone resorption, only activation of the PKC pathway induces rapid cell retraction. These two effects of calcitonin on osteoclasts are therefore independent and may be functionally unrelated.

Calcitonin effects on osteoclastic resorption: the ‘escape phenomenon’ revisited

Prolonged administration of calcitonin in vivo results in an apparent loss of respousiveness to this hormone. No controversy exists with regard to this loss of responsiveness when low to intermediate doses of calcitonin (CT) are used [l-3]. However, when high doses are administered to rats for periods up to 42 days, a persistent significant decrease in ionized calcium levels is observed [4]. Removal of the CT-releasing mini pumps at day 7 in the experiments of Lausson et al. resulted in an immediate (O-2 h after removal) increase of serum Ca, thus suggesting that the apparent loss of responsiveness was not caused by a loss of response to CT, but by compensatory mechanisms. Measurement of serum PTH levels in the experiments of Glajchen et al, indeed showed that infusion of salmon Ct (sCT) resulted in secondary hyperparathyroidism, which partially compensated the sCT-induced hypocalcaemia. This confirmed the initial suggestion by Bastian et al. [S] that the develop ment of tolerance to sCT might be due, at least in part, to an increase in endogenous parathyroid hormone secretion. In humans, loss of responsiveness to sCT during prolonged administration in patients with Paget’s disease or various osteoporotic syndromes is also observed. This has been attributed in some of the patients to formation of neutralizing antibodies [6] but occurs in others without detectable antibody formation. In bone cultures in vitro Raisz and co-workers were the first to observe that the inhibition of bone resorption by CT was transient. Their original studies [7-W] suggested that the inhibitory effect of CT on PTH-induced bone resorption in cultured rat long bone shafts lasted from 48-96 h, depended on the CT concentration used, was not due to inactivation of the hormone, was dependent on the calcium concentration of the media and occurred with salmon, human and rat CT. This phenomenon, as observed in vitro, was described as the ‘escape phenomenon’, and has since been used (and misused) frequently as the explanation for the observed loss of response to CT upon continuous administration in vivo and in vitro, Tashijan et al. [ll], in an extensive and detailed re-examination of the escape phenomenon using mouse calvariae, essentially confirmed the original observations of Raisz et al.

Regulation of cytosolic free calcium in isolated rat osteoclasts by calcitonin.

It is now established that calcium is a second messenger mediating the action of calcitonin on the osteoclast. We have demonstrated that an increase in the concentration of intracellular free calcium ([Ca2+]i) is associated with (and possibly mediates) the functional effects of calcitonin, including an acute reduction of cell spread area (the R effect) and, in the longer term, a reduction in enzyme release. The present study addresses questions relating to mechanisms of calcitonin action on osteoclast [Ca2+]i. We have used asusuberic(1-7) eel and human calcitonin as agonists, and an indo-1-based dual-emission microspectrofluorimetric method for the measurement of [Ca2+]i in single osteoclasts. Whilst asusuberic(1-7) eel calcitonin caused a biphasic increase in [Ca2+]i, human calcitonin produced only a monophasic [Ca2+]i response of a much lower magnitude. Each biphasic response consisted of a rapid initial transient increase, occurring within seconds of exposure, followed by a sustained increase in [Ca2+]i. The magnitude of the latter response was more variable, but was consistently below the peak value of [Ca2+]i. The sustained phase of the calcitonin effect was abolished in extracellular Ca(2+)-free medium. This phase is therefore dependent on extracellular [Ca2+] ([Ca2+]e) whilst the rapid transient increase appeared to be dependent on Ca2+i redistribution. The effects of calcitonin on [Ca2+]i were concentration-dependent, with neither latency nor oscillations. Repetitive 30-s exposures to calcitonin failed to produce subsequent responses. There was a marked concentration-dependent correlation between changes in osteoclast [Ca2+]i and the magnitude of the R effect. Thus the likely components of the biphasic [Ca2-]i response are a rapid redistribution followed by the transmembrane flux of Ca2+.(ABSTRACT TRUNCATED AT 250 WORDS)

Calcitonin receptor expression and its regulation by 1α,25-dihydroxyvitamin D 3 during de novo osteoclast formation in organ cultures of fetal mouse metatarsals

Organ cultures of 15-day embryonic mouse metatarsais cultured in serumless, chemically-defined medium were used to investigate the influence of 1α,25-dihydroxyvitamin D 3 (1,25(OH) 2D 3) on calcitonin receptor (CTR) expression in osteoclasts formed from in situ progenitors. CTR expression was demonstrated in tartrate-resistant acid phosphatase-positive (TRAP +) osteoclasts and their precursors. The expression of TRAP preceded that of CTR and was first observed in cells identified as osteoclast precursors. Not all TRAP + precursors were CTR + and from 40 to 60% of newly formed osteoclasts lacked CTR. Treatment with 1,25(OH) 2D 3 increased precursor numbers without affecting CTR expression, whereas both the numbers and the percentage of newly formed osteoclasts expressing CTR was increased by 1,25(OH) 2D 3. Grain count analysis revealed that this increased percentage of newly formed CTR + osteoclasts were cells with low and medium levels of CTR expression. This apparent down-regulation of CTR expression in newly formed osteoclasts may help to explain the ‘escape’ of osteoclastic bone resorption from the inhibitory effects of calcitonin.

RNA synthesis in isolated rat osteoclasts: Inhibitory effect of calcitonin

The metabolism of RNA has not been studied in the osteoclast (OC) because these bone-resorbing cells are only available in small numbers and cultures are always contaminated with other cells. Using two single-cell assay techniques, tritiated uridine ( 3H-UdR) autoradiography and gallocyanin quantitative cytophotometry, we have examined RNA synthesis in OCs isolated from neonatal rats. Oligo-nuclear OCs showed greater nuclear uptake of 3H-UdR than cells with many nuclei, and the variance of nuclear labeling within polykarya was greater in the latter, possibly because they contain nuclei of various ages. Salmon calcitonin (sCT) was a potent (ED 50 approximately 5 × 10 −12 M) and rapid (40% reduction in 2 h, 75% reduction in 6 h) inhibitor of 3H-UdR uptake, and also reduced cytochemical total cellular RNA by 22% within 4 h. Forskolin (10 −5 M) inhibited nuclear uptake of 3H-UdR, suggesting that the sCT response may be mediated by cyclic AMP. Following a short (30 min) exposure to sCT, there was a progressive decline in labeling, followed by complete recovery by 4.5 h, a response possibly related to the phenomenon of calcitonin-induced persistent activation of adenylate cyclase. Inhibition of OC RNA synthesis may be an important component of its anti-resorptive action.

Inhibitory effect of calcitonin on pure human pancreatic secretion.

The inhibitory effect of calcitonin on human pancreatic secretion was evaluated to examine whether the different results reported earlier between humans, cats and dogs can be ascribed to the different sensitivity of these species to calcitonin, as suggested by some investigators. Pancreatic juice was obtained by endoscopic cannulation of the pancreatic duct from 11 patients with relapsing pancreatitis during intravenous infusion of secretin (1 U/kg/h) plus caerulein (0.04 microgram/kg/h). After steady secretion was attained 20 min after the beginning of collection, five 2-min fractions were obtained before, and ten 2-min fractions were obtained after intravenous infusion of calcitonin (1 IU/kg/h). The pre- and post-calcitonin fractions from each patient were compared by Student's t-test. Calcitonin inhibited the secretory volume (26.8 to 65.6%) and bicarbonate secretion (21.4 to 62.0%) in 8 patients, and amylase (48.4 to 89.5%) and lipase secretion (47.4 to 90.5%) in all patients. The present studies reconfirmed that prominent inhibition of enzyme secretion occurs in humans. A new finding was that significant inhibition of the secretory volume and bicarbonate secretion occurs in humans. The inhibitory effects of calcitonin in humans did not appear to differ from those in cats and dogs, when evaluated similarly with the use of pure pancreatic juice.

Inhibitory effects of calcitonin on adenylate cyclase activity in different rat brain areas

We have investigated the effect of calcitonin (CT) on adenylate cyclase in membranes from different rat brain areas. Salmon calcitonin (sCT) dose-dependently inhibited the enzyme activity in midbrain, hypothalamus, medulla, pons and caudate nucleus, but was ineffective in adenohypophysis. The inhibitory effect was enhanced by GTP. Comparison of calcitonins of different origin indicated that sCT was the most potent in inhibiting the enzyme in hypothalamic membranes, eel CT (eCT) was slightly less potent, and human CT (hCT) was ineffective. Chronic I.C.V. pretreatment with sCT did not modify the subsequent in vitro sensitivity of adenylate cyclase to sCT. It is concluded that some of CNS actions of CT might involve modulation of intracellular cAMP levels.

Peripheral administration of eel calcitonin inhibits thyrotropin secretion in rats

The effects of peripheral administration of eel calcitonin on thyrotropin (TSH) and thyrotropin-releasing hormone (TRH) secretion were studied in rats. Eel cacitonin (50 U/kg) was injected i.v. The hypothalamic immunoreactive TRH (ir-TRH) contents increased significantly after calcitonin injection. Plasma TSH levels decreased in a dose-related manner with a nadir at 30 min after the injection. The plasma ir-TRH and TSH responses to cold as well as the plasma TSH response to TRH were inhibited by calciton.n. The inhibitory effect of calcitonin on TSH levels was prevented in the haloperidol-, pimozide- or p-chlorophenylalanine-pretreated group, but not in the L-DOPA- or 5-hydroxytryptophan-pretreated group. The findings suggest that calcitonin acts on both the hypothalamus and the pituitary to inhibit TRH and TSH release, and that its effects may be modified by amines of the central nervous system.

Interaction between amrinone and parathyroid hormone on bone in culture.

The cardiotonic agent amrinone has been postulated to directly affect Na-Ca exchange. Because stimulated bone resorption has been proposed to require Na-Ca exchange, we examined the effects of amrinone on bone. Amrinone inhibited release of Ca from neonatal mouse calvaria in organ culture stimulated by parathyroid hormone (PTH), 1,25-dihydroxyvitamin d3, or prostaglandin E2. Inhibition was dose dependent and maximal at 2 X 10(-4) M. The effect of amrinone differed from the inhibitory effects of calcitonin, ouabain, or nigericin in that 1) 6-h exposure to amrinone alone prevented the effect of subsequently added PTH; 2) amrinone was only partially effective if added after resorption was initiated by 24-h treatment with PTH; 3) coincubation with amrinone and PTH during the first 48 h of culture allowed for a response to PTH after amrinone was removed; no such protection by a stimulator occurred with ouabain or nigericin. Also submaximal concentrations of amrinone plus calcitonin, ouabain, or nigericin gave greater than additive inhibition of Ca release. Amrinone had no effect on basal bone cAMP or on the acute stimulation of cAMP by PTH. The results suggest that amrinone could have a more direct interaction with the pathway involved in stimulated bone resorption than the other inhibitors.